Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma

Parastoo B. Dahi, Roni Tamari, Sean M. Devlin, Molly Maloy, Valkal Bhatt, Michael Scordo, Jenna Goldberg, Andrew D. Zelenetz, Paul A. Hamlin, Matthew J. Matasar, Jocelyn Maragulia, Sergio A. Giralt, Miguel Angel Perales, Craig Moskowitz, Craig S. Sauter

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large Bcell lymphoma (n= 73, 37%) or mantle cell lymphoma (n= 69, 34%). One hundred and fifteen patients (57%) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60% (95% confidence interval [CI], 53% to 68%) and 73% (95% CI, 67% to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients.

Original languageEnglish (US)
Pages (from-to)2004-2009
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number12
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Cell Transplantation
Comorbidity
Disease-Free Survival
Therapeutics
Survival
Transplantation
Confidence Intervals
Mantle-Cell Lymphoma
Mortality
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Survivors
Lymphoma
Histology
Retrospective Studies
Safety

Keywords

  • Autologous transplantation
  • Elderly
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma. / Dahi, Parastoo B.; Tamari, Roni; Devlin, Sean M.; Maloy, Molly; Bhatt, Valkal; Scordo, Michael; Goldberg, Jenna; Zelenetz, Andrew D.; Hamlin, Paul A.; Matasar, Matthew J.; Maragulia, Jocelyn; Giralt, Sergio A.; Perales, Miguel Angel; Moskowitz, Craig; Sauter, Craig S.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 12, 01.01.2014, p. 2004-2009.

Research output: Contribution to journalArticle

Dahi, PB, Tamari, R, Devlin, SM, Maloy, M, Bhatt, V, Scordo, M, Goldberg, J, Zelenetz, AD, Hamlin, PA, Matasar, MJ, Maragulia, J, Giralt, SA, Perales, MA, Moskowitz, C & Sauter, CS 2014, 'Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma', Biology of Blood and Marrow Transplantation, vol. 20, no. 12, pp. 2004-2009. https://doi.org/10.1016/j.bbmt.2014.08.019
Dahi, Parastoo B. ; Tamari, Roni ; Devlin, Sean M. ; Maloy, Molly ; Bhatt, Valkal ; Scordo, Michael ; Goldberg, Jenna ; Zelenetz, Andrew D. ; Hamlin, Paul A. ; Matasar, Matthew J. ; Maragulia, Jocelyn ; Giralt, Sergio A. ; Perales, Miguel Angel ; Moskowitz, Craig ; Sauter, Craig S. / Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma. In: Biology of Blood and Marrow Transplantation. 2014 ; Vol. 20, No. 12. pp. 2004-2009.
@article{dc7420228bc54f009b56c65cecc443be,
title = "Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma",
abstract = "High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large Bcell lymphoma (n= 73, 37{\%}) or mantle cell lymphoma (n= 69, 34{\%}). One hundred and fifteen patients (57{\%}) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60{\%} (95{\%} confidence interval [CI], 53{\%} to 68{\%}) and 73{\%} (95{\%} CI, 67{\%} to 80{\%}), respectively. Transplantation-related mortality (TRM) was 4{\%} both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4{\%}) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients.",
keywords = "Autologous transplantation, Elderly, Non-Hodgkin lymphoma",
author = "Dahi, {Parastoo B.} and Roni Tamari and Devlin, {Sean M.} and Molly Maloy and Valkal Bhatt and Michael Scordo and Jenna Goldberg and Zelenetz, {Andrew D.} and Hamlin, {Paul A.} and Matasar, {Matthew J.} and Jocelyn Maragulia and Giralt, {Sergio A.} and Perales, {Miguel Angel} and Craig Moskowitz and Sauter, {Craig S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2014.08.019",
language = "English (US)",
volume = "20",
pages = "2004--2009",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-hodgkin lymphoma

AU - Dahi, Parastoo B.

AU - Tamari, Roni

AU - Devlin, Sean M.

AU - Maloy, Molly

AU - Bhatt, Valkal

AU - Scordo, Michael

AU - Goldberg, Jenna

AU - Zelenetz, Andrew D.

AU - Hamlin, Paul A.

AU - Matasar, Matthew J.

AU - Maragulia, Jocelyn

AU - Giralt, Sergio A.

AU - Perales, Miguel Angel

AU - Moskowitz, Craig

AU - Sauter, Craig S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large Bcell lymphoma (n= 73, 37%) or mantle cell lymphoma (n= 69, 34%). One hundred and fifteen patients (57%) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60% (95% confidence interval [CI], 53% to 68%) and 73% (95% CI, 67% to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients.

AB - High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large Bcell lymphoma (n= 73, 37%) or mantle cell lymphoma (n= 69, 34%). One hundred and fifteen patients (57%) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60% (95% confidence interval [CI], 53% to 68%) and 73% (95% CI, 67% to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients.

KW - Autologous transplantation

KW - Elderly

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84912105636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912105636&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.08.019

DO - 10.1016/j.bbmt.2014.08.019

M3 - Article

C2 - 25175794

AN - SCOPUS:84912105636

VL - 20

SP - 2004

EP - 2009

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -